Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBITDA Margin (2025 - 2026)

Kura Oncology has reported EBITDA Margin over the past 2 years, most recently at 409.18% for Q1 2026.

  • Quarterly EBITDA Margin fell 360.0% to 409.18% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 413.08% through Mar 2026, changed N/A year-over-year, with the annual reading at 412.56% for FY2025, 9345.0% down from the prior year.
  • EBITDA Margin was 409.18% for Q1 2026 at Kura Oncology, up from 466.62% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 356.19% in Q3 2025 and troughed at 466.62% in Q4 2025.